Author/Authors :
Guo, Mengnan Tangshan Maternal and Child Health Care Hospital - North China University of Science and Technology, Hebei, China , Li, Ning North China University of Science and Technology Affiliated Hospital, Hebei, China , Zheng, Jianxia Tangshan Maternal and Child Health Care Hospital - North China University of Science and Technology, Hebei, China , Wang, Wei Tangshan Maternal and Child Health Care Hospital - North China University of Science and Technology, Hebei, China , Wu, Yan North China University of Science and Technology Affiliated Hospital, Hebei, China , Han, Xu North China University of Science and Technology Affiliated Hospital, Hebei, China , Guo, Jiapei North China University of Science and Technology Affiliated Hospital, Hebei, China , Chen, Weixi North China University of Science and Technology Affiliated Hospital, Hebei, China , Bai, Zekun North China University of Science and Technology Affiliated Hospital, Hebei, China , Bai, Wen North China University of Science and Technology Affiliated Hospital, Hebei, China , Wu, Jinghua Tangshan Maternal and Child Health Care Hospital - North China University of Science and Technology, Hebei, China
Abstract :
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is an aggressive tumor with a high mortality rate because of the limited systemic and locoregional treatment modalities. The development and progression of HCC depend on epigenetic changes that result in the activation or inhibition of some signaling pathways. The mTOR signaling pathway is essential for many pathophysiological processes and is considered a major regulator of cancer. Increasing evidence has shown that epigenetics plays a key role in HCC biology by regulating the mTOR signaling pathway. Therefore, epigenetic regulation through the mTOR signaling pathway to diagnose and treat HCC will become a very promising strategy.
Keywords :
Epigenetic Regulation , Hepatocellular Carcinoma , Progression through , mTOR Signaling Pathway
